Probiotics And Methods Of Use
US-2016113973-A1 · Apr 28, 2016 · US
US10258656B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10258656-B2 |
| Application number | US-201615352994-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 16, 2016 |
| Priority date | May 10, 2013 |
| Publication date | Apr 16, 2019 |
| Grant date | Apr 16, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention features methods for treating or reducing the severity of a microbial infection in an infant of a lactating mother. Compositions comprising food products fermented by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 are administered to a pregnant or lactating mother in order to treat or attenuate the severity of a microbial infection in her offspring.
Opening claim text (preview).
What is claimed is: 1. A method of treating or reducing the severity of a microbial infection in an infant during gestation, the method comprising administering an effective amount of a composition comprising a food product to a pregnant mammal, wherein the food product has been fermented by the probiotic bacterium, Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778, and the probiotic bacterium rendered non-replicating after fermentation, wherein the concentration of the probiotic bacterium in the food product is at least 1×10 7 colony forming units (CFU) per gram as calculated prior to rendering the probiotic bacterium non-replicating after fermentation, wherein the microbe causing the infection being treated comprises at least one of Salmonella typhimurium and Cronobacter sakazakii. 2. The method of claim 1 , further comprising identifying an infant in need of treatment. 3. The method of claim 1 , wherein the microbe comprises Salmonella typhimurium FB62. 4. The method of claim 1 , wherein the food product is a dairy product or a cereal product. 5. The method of claim 1 , wherein the composition is administered until a symptom of the infection improves in the infant. 6. The method of claim 1 , wherein the concentration of the probiotic bacterium in the food product is between 1×10 7 and 1×10 12 colony forming units (CFU) per gram as calculated prior to rendering the probiotic bacterium non-replicating after fermentation. 7. A method of treating a microbial infection or reducing the severity of a microbial infection in an infant during gestation, the method comprising administering to a pregnant mammal an effective amount of a composition comprising probiotic bacterium Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778, wherein the probiotic bacterium has been rendered non-replicating, the concentration of the probiotic bacterium in the composition is at least 1×10 7 colony forming units (CFU) per gram as calculated prior to rendering the probiotic bacterium non-replicating, and the microbe causing the infection being treated comprises at least one of Salmonella typhimurium and Cronobacter sakazakii. 8. The method of claim 7 , wherein the microbe causing the infection being treated comprises Salmonella typhimurium FB62. 9. The method of claim 7 , wherein the composition is administered until a symptom of the infection improves in the infant. 10. The method of claim 7 , wherein the composition comprises a food product or a pharmaceutical carrier. 11. The method of claim 7 , wherein the concentration of the probiotic bacterium in the composition is between 1×10 7 and 1×10 12 colony forming units (CFU) per gram as calculated prior to rendering the probiotic bacterium non-replicating after fermentation. 12. A method of treating a microbial infection or reducing the severity of a microbial infection in an infant during gestation, the method comprising administering to a pregnant mammal an effective amount of a composition comprising a culture supernatant of probiotic bacterium Lactobacillus paracasei CBA L74 cells, International Depository Accession Number LMG P-24778, wherein the composition is administered in an amount of from 0.01 to 1,000 mg per kg based on the weight of the mother, and the microbe causing the infection being treated comprises at least one of Salmonella typhimurium and Cronobacter sakazakii. 13. The method of claim 12 , wherein the microbe causing the infection being treated comprises Cronobacter sakazakii. 14. The method of claim 12 , wherein the microbe causing the infection being treated comprises Salmonella typhimurium FB62. 15. The method of claim 12 , wherein the composition is administered until a symptom of the infection improves in the infant. 16. The method of claim 12 , wherein any Lactobacillus paracasei CBA L74 cells in the culture supernatant have been rendered non-replicating. 17. The method of claim 12 , wherein the Lactobacillus paracasei CBA L74 cells have been removed from the culture supernatant. 18. The method of claim 12 , wherein the composition comprises a food product or a pharmaceutical carrier.
Antibacterial agents · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06) · CPC title
Cereal-derived products · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.